Post-Menopausal Osteoporosis Clinical Trial
Official title:
'An Open-label Study of Patient Preference With Monthly Bonviva Therapy in Women With Post-menopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate.'
This single arm study will assess patient preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Patients currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify patients who may benefit from a monthly Bonviva regimen. Eligible patients will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg po. At the beginning and end of Bonviva treatment, all patients will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01224717 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
|
Phase 1 | |
Completed |
NCT00551174 -
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
|
Phase 4 | |
Completed |
NCT00984893 -
Intra-venous Zoledronic Acid Once Yearly
|
N/A | |
Withdrawn |
NCT01826656 -
Bone Healing in Healthy and Post-menopausal Osteoporotic Women
|
N/A | |
Completed |
NCT00718861 -
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
|
Phase 3 | |
Completed |
NCT00081653 -
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
|
Phase 4 | |
Completed |
NCT00503113 -
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
|
Phase 4 | |
Completed |
NCT00150969 -
Vitamin K Supplementation in Post-Menopausal Osteopenia
|
Phase 3 | |
Completed |
NCT03432533 -
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
|
Phase 3 | |
Completed |
NCT00533650 -
Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)
|
Phase 2 | |
Active, not recruiting |
NCT01232647 -
Vitamin K as Additive Treatment in Osteoporosis
|
Phase 2/Phase 3 | |
Completed |
NCT00666627 -
Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
|
Phase 2 |